Prof. Dr. Byoung Chul Cho | Yonsei Cancer Center, Yonsei University College of Medicine | South Korea
Prof. Byoung Chul Cho’s distinguished academic journey began with biochemistry studies at Yonsei University and an honors exchange at Oregon State University, followed by medical training at Yonsei University College of Medicine and a visiting student experience at Harvard Medical School. His clinical career advanced through internship at Asan Medical Center, residency in internal medicine at Severance Hospital, and fellowship at Yonsei Cancer Center, leading to faculty roles from instructor to professor and leadership positions including Chief of the Lung Cancer Center and Director of the Yonsei New Il Han Institute for Integrative Lung Cancer Research. His research spans precision oncology, targeted therapies, immunotherapy, RET-altered and EGFR-mutated lung cancer, and translational studies linking mechanistic insights to clinical practice. His doctoral research on Sprouty2-mediated apoptosis laid the foundation for his later breakthroughs in lung cancer biology. He has played key roles in global clinical trials, including RET inhibitor studies and LEAP-008 immunotherapy combinations that shaped treatment standards. His prolific publications have established him as a global leader in thoracic oncology. He has earned major honors such as the Wunsch Medical Award, Boryeong Research Award, Yuhan Medical Award, Minister’s Commendation for Health Technology, and multiple Highly Cited Researcher recognitions from Clarivate. His excellence in teaching is shown through repeated Best Professor Awards at Yonsei University. His influence extends through active involvement in ASCO, ESMO, IASLC, SITC, and major Korean oncology societies. Prof. Cho’s impact continues to grow through innovative research, mentorship, and leadership that shape the future of precision lung cancer care worldwide.
Profile: Orcid
Featured Publications
Yang, J. C.-H., Lu, S., Hayashi, H., Felip, E., Spira, A. I., Girard, N., Kim, Y. J., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., et al. (2025). Overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC. New England Journal of Medicine. Advance online publication.
Krebs, M. G., Cho, B. C., Hiret, S., Han, J.-Y., Lee, K. H., Perez, C. L., De Braud, F., Haura, E. B., Sanborn, R. E., Yang, J. C.-H., et al. (2025). Amivantamab in participants with advanced NSCLC and MET exon 14 skipping mutations: Final results from the CHRYSALIS study. Journal of Thoracic Oncology.
Ahn, M.-J., Cho, B. C., Ohashi, K., Izumi, H., Lee, J.-S., Han, J.-Y., Chiang, C.-L., Huang, S., Hamidi, A., Mukherjee, S., et al. (2025). Asian subgroup analysis of patients in the phase 2 DeLLphi-301 study of tarlatamab for previously treated small cell lung cancer. Oncology and Therapy.
Lee, J. B., Shim, J. S., & Cho, B. C. (2025). Evolving roles of MET as a therapeutic target in NSCLC and beyond. Nature Reviews Clinical Oncology.
Park, S., Ahn, H. K., Lee, S., Min, Y. J., Kim, J., Jung, H. A., Sun, J.-M., Lee, S.-H., Ahn, J. S., Ahn, M.-J., et al. (2025). Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A phase II multicenter trial. Journal of Thoracic Oncology.